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Background: The mechanisms of drug resistance of cancer have not been yet elucidated in details. Recently, the role of mast cells 
(MCs) in the development of drug resistance has been brought in the limelight. The aim of the study was to examine the morphologi-
cal features of doxorubicin (DOX)-resistant Walker 256 carcinosarcoma and to assess the response of MCs and histamine content 
in these cells in relation to the development of resistance to DOX as well as in DOX-resistant tumors. Materials and Methods: 
The DOX resistance was induced by serial passages of Walker 256 carcinosarcoma in rats in the setting of DOX treatment in vivo. 
MCs in tumors were detected in the sections by staining with Toluidine Blue O. Histamine content in MCs stained with solution 
of Water Blue-Orcein was assessed by Astaldi semiquantitative method taking into account different staining intensity. Results: 
Formation of DOX resistance in the course of serial passages of Walker 256 carcinosarcoma was accompanied by the increase in the 
number of MCs in tumors and histamine content. Nevertheless, in tumors with phenotype of complete DOX resistance the number 
of histamine-containing MCs decreased to the same level as in tumors of the original strain that are DOX-sensitive. Conclusion: 
MCs are involved in formation of DOX resistance in Walker 256 carcinosarcoma.
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Cancer drug resistance is one of the main factors 
limiting effectiveness of antineoplastic therapy. The 
mechanisms of both primary resistance featuring 
the intrinsic properties of cancer cells and acquired 
resistance arising as an adaptive response to che-
motherapeutics of various groups are in the spotlight. 
Nevertheless, the mechanisms involved in the devel-
opment of the resistance to anthracyclines have not 
been studied in depth.
Besides, in recent years, interest in properties 
of the mast cells (MCs) has increased due to their 
multifunctionality and involvement in adaptive re-
sponses and pathological processes. MCs population 
is heterogeneous. According to their protease content, 
human MCs have been divided into two phenotypes: 
those containing only tryptase, termed MCT, and 
those containing both tryptase and chymase, termed 
MCTC. MCT are found in mucosa while MCTC are con-
sidered as MCs of connective tissue type [1]. MCs are 
heterogeneous by many other factors: localizations, 
content of granules, response to different stimulation 
and pharmacological agents [2]. Nevertheless, such 
classification is rather conventional since MCs can 
dynamically change their properties according to the 
conditions of microenvironment [1]. On their surface, 
MCs express receptors to chemokines, immunoglobu-
lins (IgA, IgE, IgG), adrenaline, adenosine, estrogen, 
leptin, histamine, serotonin, stem cell factor, etc [2].
MCs are capable of affecting tumor development, 
angiogenesis, and adaptive immune reactions [3, 4]. 
Due to proteases, MCs are involved in stroma remod-
elling, which promotes invasion and metastasizing 
of tumor cells [5, 6]. It is shown that density of MCs 
increases with tumor progression [7]. Nevertheless, 
there is no consistent view on the mechanisms of how 
MCs affect tumor growth. Two hypotheses of interac-
tions between tumor and MCs exist. According to the 
first hypothesis, MCs stimulate carcinogenesis due 
to the expression of proteases, angiogenic and growth 
factors. According to the second hypothesis, MCs, 
on the contrary, possess cancer suppressive proper-
ties. The biological effects of MCs are mediated by the 
range of substances released by these cells. Therefore, 
the net effect of MCs on tumor growth depends on the 
complex interactions between these substances and 
stroma cells (endotheliocytes and fibroblasts) [8]. The 
heterogeneous phenotype both of cancer cells and 
MCs as well as the opposite effects of various factors 
in such interplay should also be taken into account.
Histamine is one of the mediators involved in regu-
lation of wide range of physiological and pathological 
processes in which MCs are the main factors. This low-
molecular monoamine participates in cell proliferation 
and differentiation, hematopoiesis, regeneration, 
wound healing, signal transduction in aminergic neu-
rons, and also in a number of brain functions, in inflam-
mation and modulation of the immune response [9].
Histamine plays an important role in physiological 
and pathological processes in mammary glands being 
involved in growth regulation, differentiation and func-
tion in pregnancy and lactation [10]. Four subtypes 
of histamine receptors (H1, H2, H3 and H4) have been 
revealed in mammary glands. Activation of H2 and 
H3 receptors promotes proliferation of cancer cells 
in vitro, while activation of H1 and H4 receptors inhib-
its such proliferation [11]. Also, histamine may affect 
tumor indirectly via activation of angiogenesis [12]. 
Histamine possesses both proangiogenic and antian-
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giogenic properties depending on its concentration, 
availability of cofactors and tumor microenvironment. 
Nevertheless, histamine seems to affect angiogenesis 
not directly but via endothelial cells in cooperation with 
other proangiogenic factors.
The role of histamine in metastasizing is well known. 
The expression of MMR-2 and MMR-9 in breast cancer 
cells in vitro varies depending on histamine concentra-
tion, this effect being mediated by H2 and H4 [13]. Due 
to H1 activation, histamine modulates MMR-2 activity 
not only in cancer cells but also in fibroblasts [14].
The role of MCs in the development of resistance 
to chemotherapeutic agents has not yet been clarified. 
Study of the factors triggering doxorubicin (DOX) resis-
tance suggests that tumor cell-to-extracellular matrix 
interactions are important. The purpose of the study 
was to examine the morphological features of DOX-
resistant Walker 256 carcinosarcoma and to assess 
the response of MCs and histamine content in these 
cells in relation to the development of DOX resistance.
MATERIALS AND METHODS
The rats from the animal facility of R.E. Kavetsky 
Institute of Experimental Pathology, Oncology and 
Radiobio logy, the National Academy of Sciences 
of Ukraine (Kyiv, Ukraine) were used in the study. The 
use and care of the experimental animals was per-
formed in accordance with the standard international 
rules of biologic ethics and was approved by Institu-
tional Animal Care and Use Committee. Wal ker 256 car-
cinosarcoma was obtained from National Repository 
of Cell Lines and Transplanted Tumors of R.E. Kavetsky 
Institute of Experimental Pathology, Oncology and 
Radiobio logy. The rats were inoculated with original 
Walker 256 tumor cells or cells of DOX- resistant strain. 
Walker 256 carcinosarcoma with induced resistance 
to DOX was obtained as described earlier by serial 
transplantation of tumor cells in DOX-treated animals 
(12 in vivo passages in total) [15, 16]. The tumors of the 
parental strain, the tumors after four in vivo passages 
in DOX setting (partial DOX resistance), and the tumors 
of the refractory phenotype (complete DOX resistance) 
were studied. The separate group of the rats bearing 
Walker 256 carcinosarcoma of the refractory phe-
notype was treated with DOX at a dose of 1.5 mg/kg 
(accumulated dose of 7.5 mg/kg), and such tumors 
were also evaluated.
MCs in tumors were detected by staining with 1% 
solution of Toluidine Blue O, (Sigma-Aldrich, USA) 
in 0.5 M HCl by the standard technique [17] and 
counted as per 1 mm2 of tumor tissue [18].
Histamine in MCs was detected in the sections 
stained with solution of Water Blue — Orcein [19]. 
The results of cytochemical reaction were expressed 
as a percentage of positive cells [20]. Histamine con-
tent in MCs was assessed by Astaldi semiquantitative 
method, taking into account different staining intensity 
(weak, moderate or intensive) in 100 cells.
The statistical analysis of data was carried out 
by method of variation statistics using Microsoft Excel 
2010 (Microsoft Corp., USA). The arithmetic mean 
and its error (M ± m) were calculated. The statistical 
significances of differences between mean values 
were assessed with Student’s t-test. Differences 
at p < 0.05 were considered significant.
RESULTS
Morphological features of Walker 256 carci-
nosarcoma. In 6 days after transplantation of paren-
tal strain of Walker 256 carcinosarcoma, tumor node 
of 2.3 ± 0.3 cm was evident. Tumor cells were bunched 
in bundles and layers or solid complexes plunged into 
muscular tissue here and there and sprouted along 
muscle fibers and blood vessels disarranging the struc-
tural architectonics of skeletal muscles. Sarcomatous 
cells with hyperchromic nuclei varied in form (spindle, 
stellated) and size. Epithelioid cells were distinguished 
by moderate polymorphism and had mainly hypochro-
mic nuclei. In these cells, individual mitoses have been 
observed. On the periphery of tumor node, epithelioid 
cells formed so-called pseudo-follicular structures and 
solid layers. The tumors were, as a rule, limited to the 
surrounding sarcomatous stroma (Fig. 1). At the center 
of the tumor, the tissue was less structured than on the 
periphery, polymorphism of cells and nuclei was less 
expressed. Necrotic foci of various sizes were observed.
Fig. 1. Walker 256 carcinosarcoma: pseudo-follicular structures (1) 
and solid bundles (2) (stained with hematoxylin and eosin, x 200)
In 16–18 days after transplantation, the tumor 
node took on more structured patterns with formation 
of pseudo-follicular structures and outgrowth of the 
bundles of sarcomatous cells with light epithelioid 
cells located between them. At sites of proliferation, 
active angiogenesis with ingrowth of blood vessels 
into the tumor has been observed. The remaining 
muscle fibers were lysed. In the center of tumor node, 
necrotic foci have been observed. The increased 
number of apoptotic cells has been evident.
MCs in Walker 256 carcinosarcoma tumors. 
A small number of MCs was detected at the central 
sites of the tumors (6.7 ± 1.3 cells per 1 mm2), some 
of them with metachromatically stained granularity; 
some grains sticking together (Fig. 2). Most of these 
cells were destroyed partially or completely. In MCs 
that seem to be intact, specific granules exited outside.
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Fig. 2. MCs in a section of Walker 256 carcinosarcoma (control) 
(stained with Toluidine Blue O, × 400)
It is necessary to notice that MC count (up to 15–
20 per 1 mm2) increased when the inflammation foci 
were observed. In such cases, MCs were larger and 
contained specific metachromatic granularity in a cy-
toplasm. Observed degranulation of MCs with the 
release of the specific granules seems to indicate their 
functional activity. Such cells were found mainly at the 
peripheral sites of tumor node.
Morphological changes of Walker 256 carcino-
sarcoma throughout formation of DOX resistance 
and in DOX-resistant tumors upon DOX treatment. 
In tumors with partial DOX resistance (four in vivo 
passages in DOX setting), tumor cells were less poly-
morphic. Light epithelial cells in clusters prevailed, 
in particular, on the periphery of tumor node. At the 
central sites of tumor, cells with moderate nuclear 
polymorphism were predominant along with the ne-
crotic foci. The number of blood vessels of capillary 
type increased. Also, in comparison with original 
tumors, partially resistant tumors were characterized 
by more structured patterns with formation of pseudo-
follicular structures and the cords of sarcomatous cells 
with dark hyperchromatic nuclei.
In tumors with complete DOX resistance, vascular-
ization further enhanced, mainly at the expense of the 
vessels of capillary type with increasing hemorrhages 
accompanying with infiltration and plasmatic suffu-
sion of the tumor. In the central zones of the tumor, 
the necrotic foci of various size, mainly infiltrated with 
neutrophils and monocytes were observed. On the 
periphery, tumor cells were bunched in bundles and 
layers of solid complexes that plunged into muscular 
tissue, while the remnants of muscles were also evident 
(Fig. 3). Epithelioid cells of moderate polymorphism 
and with prevalence of hypochromic nuclei prevailed 
and formed pseudofollicular structures and solid lay-
ers with bundles of sarcomatous cells. The number 
of mitoses in these cells increased. The pathological 
mitoses were also evident.
DOX treatment of the rats bearing DOX-resistant 
Walker 256 tumors has not changed substantially 
the morphology of tumors. Epithelioid cells remained 
prevalent but fibrotization increased in comparison 
with resistant type (Fig. 4). Furthermore, the signifi-
cant vascularization mainly at the expense of capillary 
vessels and increasing numbers of hemorrhages was 
evident.
Fig. 3. The cords of Walker 256 carcinosarcoma DOX-resistant 
tumor cells growing into muscular tissue (stained with hema-
toxylin and eosin, × 400)
Thus, with increasing DOX resistance of Walk-
er 256 carcinosarcoma the number of capillary vessels 
increased, epithelioid cells being the main component 
of tumors. The fibrotization of tumor node was also 
observed. Upon DOX treatment of DOX-resistant type 
of Walker 256 carcinosarcoma, the features above 
became more prominent.
Fig. 4. Elements of connective tissue (1), hemorrhages (2), 
vessels (arrows) in DOX-resistant Walker 256 carcinosarcoma 
upon DOX treatment (stained with hematoxylin and eosin, × 400)
MCs in Walker 256 carcinosarcoma throughout 
formation of DOX resistance and in DOX-resistant 
tumors upon DOX treatment. In tumors with partial 
DOX resistance, MCs located mainly in connective 
tissue layers. Occasionally, MCs were observed near 
blood vessels. Granules in cytoplasm did not stick 
together suggesting MC metabolical activation. Some 
granules were found extracellularly while MCs remain 
intact.
In tumors with complete DOX resistance, MCs lo-
cated centrally or among pseudo-follicular structures, 
or near blood vessels. The insignificant part of such 
cells was degranulated with the granules exiting the 
cells while a fraction of granules remaining in a cy-
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toplasm (Fig. 5). MCs were also found in connective 
tissue structures surrounding tumor node.
Fig. 5. MCs (arrows) in central zones of DOX-resistant Wal-
ker 256 carcinosarcoma (stained with Toluidine Blue O, × 400)
After DOX treatment, the number of MCs in DOX-
resistant tumors increased compared to that in DOX-
resistant tumors of animals which were not DOX treated 
(Fig. 6). These cells localized predominantly in the 
connective tissue components of tumors and near the 
vessels of capillary type crowded with erythrocytes. 
In cytoplasm of the most part of these MCs, disperse 
granules were visible with increased number of the 
degranulated cells wherein specific granules being 
released extracellularly.
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Fig. 6. The number of MCs in DOX-resistant Walker 256 carcinosar-
coma in animals treated or non-treated with DOX. *р ≤ 0.05 com-
paring with control
Histamine content in MCs in Walker 256 car-
cinosarcoma throughout formation of DOX resis-
tance and in DOX-resistant tumors upon DOX treat-
ment. In animals bearing original Walker 256 tumor, 
histamine-containing MCs were observed mainly near 
blood vessels, on the periphery of tumor node, and also 
at the sites where tumor cords grew into the muscles 
(Fig. 7). In partially resistant tumors, the number of his-
tamine-containing MCs increased significantly (Fig. 8, 
9) while the count of MCs in completely resistant tumors 
dropped to the initial level in the original tumor (Fig. 9). 
DOX treatment of animals with DOX-resistant tumor 
did not further affect histamine-containing MC count.
The percentage of histamine-positive MCs with inten-
sive staining increased with increasing DOX resistance 
with the concomitant decrease in the number of moder-
ate and poorly stained histamine-positive MCs (Fig. 10).
DISCUSSION
As was shown earlier, the formation of complete 
DOX resistance of Walker 56 carcinosarcoma in rats 
requires 12 passages in the setting of DOX treatment 
in vivo [15]. Four courses of chemotherapy result 
in partial DOX resistance with tumor growth inhibi-
tion by about 30%, while DOX treatment inhibited 
the growth of parental Walker-256 carcinosarcoma 
by about 65% [16]. These two time-points correspond-
ing to partial (4 passages) and complete (12 pas-
sages) DOX resistance were selected for studying the 
morphological features of Walker 256 carcinosarcoma 
Fig. 7. MCs (arrows) at the site of tumor ingrowth into muscular 
tissue (stained with Water Blue — Orcein, × 200)
Fig. 8. MCs (arrows) in central zones of Walker 256 carcinosar-
coma with phenotype of partial resistance (stained with Water 
Blue — Orcein, × 200)
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Fig. 9. The number of histamine-containing MCs in DOX-
resistant Walker 256 carcinosarcoma in animals treated or non-
treated with DOX. *р ≤ 0.05 comparing with control
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and the biology of MCs in dynamics of the formation 
of DOX resistance.
Morphologically, in DOX-resistant tumors we have 
found more structured patterns with formation of pseu-
do-follicular structures, slight outgrowth of the bundles 
of sarcomatous cells, and the activation of neoan-
giogenesis. MCs response was also evident with the 
increasing functional activity of these cells manifested 
as their degranulation with the release of the specific 
granules. The data obtained correspond to the re-
sults of other researchers who showed the increased 
MC count, basically, at the peripheral sites of a tumor 
and surrounding tissues [21, 22] with degranulation 
of single MCs in the centre of tumors [23]. The slight 
increase in the number of these cells with small content 
of intracytoplasmic granules was observable mainly 
near small vessels.
In DOX-resistant tumors, the outgrowth of connec-
tive tissue component with fibrotization of tumor node 
was noted. This fact can be explained by MC contri-
bution to remodeling of connective tissue structures 
due to the activity of the matrix proteinases and 
proteinases located in MC granules as well as the 
intensification of collagen synthesis by activated fi-
broblasts [24]. The significant vascularization in DOX-
resistant tumors seemed to be associated in part with 
known MC effects on angiogenesis due to histamine 
and VEGF [25, 26].
Two biologically active agents produced by MCs, 
heparin and histamine, acting oppositely play an im-
portant role in regulation of MC effects [27]. The an-
tagonism of these substances is the cornerstone of the 
functional duality of MCs acting both in stimulation and 
inhibition mode.
The number of MCs in DOX-resistant tumors se-
quentially increased, and the number of MCs contain-
ing histamine decreased. It is known that DOX may 
stimulate secretion of histamine by MCs [28, 29] simi-
larly to substance 48/80, which leads to degranulation 
of MCs. This occurs because heparin and chondroitin 
sulfate are protein glycanes with strong negative 
charge while DOX has a positive charge facilitating its 
binding with heparin and protein glycanes that, in turn, 
stimulates histamine release from MCs.
The phenotype of DOX resistance in Walk-
er 256 carcinosarcoma is associated also with 
changes in chemical signals produced by the 
cells of resistant tumors. The mediators secreted 
by tumor cells may affect immunocompetent cells 
changing the patterns of their synthesis and se-
cretion [30]. In this setting, the response of MCs 
is expressed not only as an increase in MC number 
but also in changing patterns of mediators located 
in cytoplasm of these cells (both preformed and 
newly synthesized). In particular, we have shown 
that histamine content in MCs upon DOX treatment 
decreased. But the decrease in histamine content 
does not imply the decrease in their functional ac-
tivity. On the contrary, histamine is released from 
cytoplasmatic granules into extracellular space. The 
released histamine may enhance proliferation of tu-
mor cells, stimulate angiogenesis, increase activity 
of matrix metalloproteinases (ММР-2 and ММР-9) 
and provide for immunomodulating effect on im-
mune competent cells (macrophages, T-cells) [9, 
13]. As to the stimulation of angiogenesis, we in fact 
demonstrated the increased density of capillaries 
in DOX-resistant tumors. Also, histamine is capable 
to increase expression of periostin and collagen 
І in fibroblasts [31] possibly contributing in the in-
creased fibrotization of tumor node demonstrated 
in DOX-resistant tumors.
Our data are in line with the current opinion that 
MСs are important in regulating different functions 
relevant to pathogenesis of tumors and adaptation 
of tumor-bearing host to the extreme factors including 
chemotherapeutical agents. We have shown that MCs 
involved in extracellular matrix remodeling contribute 
to the formation of DOX resistance of Walker 256 car-
cinosarcoma.
REFERENCES
1. Moon TC, Laurent CD, Morris KE, et al. Advances 
in mast cell biology: new understanding of heterogeneity and 
function. Mucosal Immunol 2010; 3: 111–28.
2. Molderings GJ. Mast cell function in physiology and 
pathophysiology. Biotrend Rev 2010; 5: 1–11.
3. Мarichal T, Tsai M, Galli S. Mast cells: potential posi�
tive and negative roles in tumor biology. Cancer Immunol Res 
2013; 1: 269–79.
4. Lazarev AF, Bovrov IP, Cherdantseva TM, et al. Mast 
cells and tumor growth. Siberian Oncol J 2011; 46: 59–
63 (in Russian).
5. Maltby S, Khazaie K, McNagny KM. Mast cells 
in tumor growth: angiogenesis, tissue remodelling and im�
munomodulation. Biochim Biophys Acta 2009; 1796: 19–26.
6. Ch’ng S, Wallis RA, Yuan L, et al. Mast cells and cutane�
ous malignancies. Mod Pathol 2006; 19: 149–59.
7. Crivellato E, Nico B, Ribatti D. Mast cell contribution 
to tumor angiogenesis: a clinical approach. Eur Cytokine 
Network 2009; 20: 197–206.
8. Kondashevskaya MV. Mast cells and heparin — key links 
in adaptive and pathological processes. Vestnik RAMS 2010; 
6: 49–54 (in Russian).
9. Shahid M, Tripathi T, Sobia F, et al. Histamine, hista�
mine receptors, and their role in immunomodulation: an up�
dated systematic review. Open Immunol J 2009; 2: 9–41.
0
10
20
30
40
50
60
Weak Moderate Strong
Pe
rc
en
t o
f c
el
ls
Control
Partial DOX resistance
Complete DOX resistance
Complete DOX resistance + DOX
*
*
* * *
*
*
*
Fig. 10. Distribution of histamine-containing cells by staining 
intensity.*р ≤ 0.05 comparing with control
Experimental Oncology 40, 42–47, 2018 (March) 47
10. Wagner W, Ichikawa A, Tanaka S, et al. Mouse mam�
mary epithelial histamine system. J Physiol Pharmacol 2003; 
54: 211–23.
11. Medina VA, Rivera ES. Histamine receptors and 
cancer pharmacology. Brit J Pharmacol 2010; 161: 755–67.
12. Qin L, Zhao D, Xu J, et al. The vascular permeabilizing 
factors histamine and serotonin induce angiogenesis through 
TR3/Nur77 and subsequently truncate it through thrombos�
pondin�1. Blood 2013; 121: 2154–64.
13. Cricco G, Mohamad N, Sáez MS, et al. Histamine and 
breast cancer: a new role for a well known amine. In: Breast 
cancer — carcinogenesis, cell growth and signalling pathways. 
M Gunduz, E Gunduz, eds. InTech, 2011: 611–34.
14. Porretti JC, Mohamada NA, Martína GA, et al. Fi�
broblasts induce epithelial to mesenchymal transition in breast 
tumor cells which is prevented by fibroblasts treatment with 
histamine in high concentration. Int J Biochem Cell Biol 
2014; 1: 29–38.
15. Todor IN, Lukyanova NY, Shvets YV, et al. Metabolic 
changes during development of Walker�256 carcinosarcoma 
resistance to doxorubicin. Exp Oncol 2015; 37: 19–22.
16. Chekhun VF, Lozovska YuV, Burlaka AP, et al. Remo�
dulating effect of doxorubicin on the state of iron�containing 
proteins, and redox characteristics of tumor with allowance 
for its sensitivity to cytostatic agents. Ukr Biochem J 2016; 
88: 99–108.
17. Krishnaswamy G, Chi DS. Mast cells methods and 
protocols. Humana Press Inc, 2006. 439 p.
18. Derman GL, Piten’ko NN. Morphology and histo�
chemistry of plasmatic and mast cells in tumors of mammary 
gland. Arch Path 1969; 31: 45–51 (in Russian).
19. Kimoto H, Oda T. Detection of histamine in rat mast 
cell granules by orcein�water blue stain. Acta Histochem Cy�
tochem 1979; 12: 292–300.
20. Laboratory diagnostic techniques in clinics. VV Men�
shikov, ed. M: Medicine, 1987. 368 p. (in Russian).
21. Pyziak L, Stasikowska�Kanicka O, Danilewicz M, 
et al. Immunohistochemical analysis of mast cell infiltrates 
and microvessel density in oral squamous cell carcinoma. Pol 
J Pathol 2013; 64: 276–80.
22. Samoszuk M, Kanakubo E, Chan JK. Degranulating 
mast cells in fibrotic regions of human tumors and evidence that 
mast cell heparin interferes with the growth of tumor cells through 
a mechanism involving fibroblasts. BMC Cancer 2014; 1: 1–10.
23. Dzodzikova ME, Shakhlamov VA, Berezov TT, 
et al. Mast cells in process of forming tumor of mammary 
gland in an experiment. Proc Vladikavkaz Sci Center 2003; 
3: 37–43 (in Russian).
24. Liu J, Zhang Y, Zhao J, et al. Mast cell: insight into 
remodeling a tumor microenvironment. Cancer Metastasis 
Rev 2011; 30: 177–84.
25. Kunder CA, John AL, Abraham SN. Mast cell modu�
lation of the vascular and lymphatic endothelium pathogens. 
Blood 2011; 118: 5383–93.
26. Conti P, Casteffani ML, Kempuraj D, et al. Role 
of mast cells in tumor growth. Ann Clin Lab Sci 2007; 
37: 315–22.
27. Katsuba AE, Chertok VM, Kotsuba E, Babich EV. Spe�
cial aspects of cytochemistry of mast cells in some organs 
of a rat. Cytology 2008; 50: 1023–9 (in Russian).
28. Decorti G, Klugmann FB, Crivellato E, et al. Bio�
chemical and microscopic evidence for the internalization 
of drug�containing mast cell granules by macrophages 
and smooth muscle cells. Toxicol Appl Pharmacol 2000; 
169: 269–75.
29. Estévez MD, Vieytes MR, Botana LM. Study of the 
activation mechanism of adriamycin on rat mast cells. Agents 
Actions 1994; 42: 86–91.
30. Hanahan D, Coussens LM. Accessories to the 
crime: functions of cells recruited to the tumor microenviron�
ment. Cancer Cell 2012; 21: 309–22.
Copyright © Experimental Oncology, 2018
